DOCSLIB.ORG

The Next Generation of Precision Medicine – Bioelectronics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Next Generation of Precision Medicine – Bioelectronics 61 The next generation of Precision Medicine – Bioelectronics The JournalMedicine of Precision An interview with Michael Heltzen and Brett Goldsmith MANY EFFORTS IN the past have been made Goldsmith of Cardea Bio to ask a few questions Bio-Layer Interferometry (BLI), next-generation to link biology directly to various read-out on the technology and applications of the device sequencing (NGS), etc.), many of which contain technologies to make molecular control signals directed to how this platform could be used to outdated methods and technology (e.g. sample accessible for monitoring in near-real time. advance precision medicine in drug development prep for optics) nearly a half-century old. Cardea Bio has taken up this challenge with a new and in the clinic. Optics-based technologies (SPR, BLI) class of devices that transduce biological binding contain an inherent limitation when it comes to surface events to a signal generated in a substrate. Q1. What are the benefits that Cardea Bio measurement; the molecules they aim to detect The key to Cardea’s approach is to stabilize brings to the market compared to are often smaller than the wavelengths of light receptor biomolecules on the gate of a graphene related measurement platforms in terms needed to observe them optically. As a result, for transistor that bridge biology binding events of e.g., sensitivity, selectivity, speed? example, technologies that measure nucleotides on the transistor’s surface to an electrical signal In this regard, how does Cardea Bio (e.g. NGS) require the mass-amplification of the in the transistor’s substrate. Cardea Bio’s mission differentiate its performance relative target molecule to meet the minimum threshold for is to provide a means to connect digital networks to competitive systems? detection. Additionally, optics-based technologies (the Internet, computers, and our cell phones) cannot directly detect amino acids; rather, they to the networks of biomolecular signals measure A. The Cardean Infrastructure has several distinct rely on secondary tags bound to the target to by the device. advantages over traditional measurement platforms produce a detectable signal, providing an indirect We contacted Michael Heltzen and Brett (lateral flow, surface plasmon resonance (SPR), approximation at best. Where optics-based Journal of Precision Medicine | Volume 7 | Issue 2 | June 2021 thejournalofprecisionmedicine.com @journprecmed Journal of Precision Medicine | Volume 7 | Issue 2 | June 2021 62 Figure 1: A diagram describing the action of the Cardean biology gated transistor. A capture chemistry such as an antibody is connected to the graphene surface. The graphene is constructed to be part of a liquid gated transistor. At the start, there is nothing bound to the capture chemistry. technologies provide a snapshot of a biological detect biomarkers in minutes, as well as binding learning algorithms that improve accuracy and interaction, electronic detection provide a near-real activity without amplification, including whole sample-to-answer times as well as letting us gain an time monitoring capability over the course of the genes, single nucleotide polymorphisms (SNPs), understanding of the biology. The current generation experiment. Finally, many traditional technologies and small molecules. of Cardea Infrastructure is already capable of require cumbersome equipment, complex We further potentiate the capabilities of direct unparalleled sensitivity, selectivity, and speed. protocols, and extensive training. electrical detection by using graphene at the core The Cardean Infrastructure overcomes of our transistor. Graphene is highly biocompatible, Q2. What portfolio of assays does limitations of optics-based technologies. unlike gold and silicon because it can operate Cardea Bio envision for precision Cardea’s direct detection does not rely on any directly in salt-solutions, such as biological fluids. medicine applications: tags that can interfere with the biomolecules It is also very sensitive to changes in its charge The JournalMedicine of Precision being studied, or cause non-specific interference environment such as those caused when two In drug development? that can influence results, as with optical molecules bind near the surface. When our target A. Cardean transistors are used by our partners technologies. Cardea is able to directly read and binds to the capture mechanism immobilized to the to do drug discovery via primary and secondary quantitate the biological signal in question in surface of our transistor, the binding event changes screenings, especially with respect to “hit to lead” near real time in live data streams. Our system the electrical properties of the graphene that can validation. This adds another fast, cost-effective, can detect molecules that are smaller than visible then be read as a robust signal (as diagrammed in platform that has demonstrated comparable rank wavelengths of light – allowing us to directly Figures 1 and 2). These signals are fed into machine ordering to BLI.1 Figure 2: A diagram describing the action of the Cardean biology gated transistor after exposure to the analyte. Binding to the capture chemistry causes a change in the overall transistor properties. Journal of Precision Medicine | Volume 7 | Issue 2 | June 2021 thejournalofprecisionmedicine.com @journprecmed Journal of Precision Medicine | Volume 7 | Issue 2 | June 2021 In clinical trials? rapid stratification of patients to the appropriate Q5. What are Cardea’s plans with A. Cardea’s platform could be used for a wide treatment. The opportunity with cancer treatments respect to FDA approval and marketing range of applications during clinical trials. is a great example of this. The use of liquid biopsy its products? Does Cardea Bio intend From real-time pharmaco-kinetics (PK), to techniques, such as with our InterCell-Chip to market an FDA-approved in vitro biomarker assays, to genetic screening for (for intercellular communication) or CRISPR- diagnostic kit, or will it go the laboratory- inclusion/exclusion criteria, and many more; each Chip sets (for gene or SNP mutations), presents developed test route? of these presents an opportunity for our partners an opportunity not only to diagnose cancer early, to provide a cutting-edge technology to support but also to assess which treatment would be A. Cardea works by enabling our Innovation clinical trials. most effective in the context of identified genetic Partners to utilize this technology to create mutations or abnormalities, active cellular destress disruptive products in their markets. This universe In the clinic? signals, or evidence of cancer cells hijacking of opportunities for Cardea runs the breadth of A. We see our technology as enabling in the field cellular components like exosomes to metastasize. markets, both regulated and unregulated. For our of rapid point of care (POC)/point of testing in The beauty of our system is its imminent ability partners in regulated markets, we help their ways not available previously. From enzymatic to combine several individual tests into one regulatory and commercial teams to devise an assays for newborn screening to infectious disease multi-omics chip. Instead of sending a sample to appropriate route, whether a cleared IVD kit or diagnostics to monitoring of immune responses sequencing, another for an immunoassay, and a a CLIA-waived LDT depending on the market after vaccination or immunotherapies, our partners third to enzymatic assay, our partners will be able and the application. Cardea then relies on its have the ability to provide a transformational to build products that combine it all on a single partners to market and distribute their “Powered way to understand patient health in prognostic, disposable chip. Thus, a physician will get a more by Cardea” product. diagnostic, or monitoring scenarios. complete and near instant picture of a patient’s 63 condition and can use those actionable insights Q6. What are Cardea Bio’s plans for In the R&D lab? to improve patient outcome. regulatory compliance in the US, the UK, A. R&D labs instruments and “quality control” the EU, and elsewhere? Does Cardea Bio applications like www.CRISPRqc.com are have a roadmap and strategy along the fastest moving markets we see in regard ‘Linking up to Life’ these lines? to deploying our technology via product Cardea is on a long-term mission, “Linking up A. development. This path offers a combination of to Life,” to empower its “Powered by Cardea” As a manufacturer of biosensors that will no or low regulatory hurdles and a strong market partners with Tech+Bio solutions that will enable be integrated into a wide variety of products, demand to solve a number of costly problems and impact via innovative applications. we intend to seek ISO 9001 and ISO 13485 bottlenecks identified and well understood by our For more information about Cardea Bio Inc. certifications. We believe this will be a critical “Powered by Cardea” partners. visit www.cardeabio.com path for us to support our partners in regulated markets, and we are a firm believer in providing Q3. Does Cardea Bio plan to develop safe and effective products for our partners companion diagnostics application for, say, Q4. In follow up to Q2 and Q3, and their consumers. Each product we design The JournalMedicine of Precision an assessment of a patient in a doctor’s what sample types does the Cardea with our Innovation Partners would require an office for a therapy? platform support – blood, sputum, individualized regulatory strategy determined by urine? What types of sample our Partner’s commercial goals and intended use A. Companion diagnostics represent a great place preparation are needed for in-office market. We work with our Partners to identify the for our future partners to utilize our technology for of in-laboratory applications? most effect roadmap for each product to create a win-win partnership that delivers safe and effective A. Being an all-electric system that does not products quickly to consumers. rely on optics, the platform can function in any biological fluid sample. The sample preparation Q7.
Load more

Recommended publications
  • Biosensors and Bioelectronics 142 (2019) 111530
    Biosensors and Bioelectronics 142 (2019) 111530 Contents lists available at ScienceDirect Biosensors and Bioelectronics journal homepage: www.elsevier.com/locate/bios Highly sensitive bioaffinity electrochemiluminescence sensors: Recent T advances and future directions ∗ Bahareh Babamiria,b, Delnia Baharia,b, Abdollah Salimia,b,c, a Department of Chemistry, University of Kurdistan, 66177-15175, Sanandaj, Iran b Research Center for Nanotechnology, University of Kurdistan, 66177-15175, Sanandaj, Iran c Department of Chemistry, University of Western Ontario, N6A 5B7, London, Ontario, Canada ARTICLE INFO ABSTRACT Keywords: Electrogenerated chemiluminescence (also called electrochemiluminescence and abbreviated ECL) has attracted Electrochemiluminescence much attention in various fields of analysis due to the potential remarkably high sensitivity, extremely wide Bioaffinity sensors dynamic range and excellent controllability. Electrochemiluminescence biosensor, by taking the advantage of Aptasensor the selectivity of the biological recognition elements and the high sensitivity of ECL technique was applied as a Immunoassays powerful analytical device for ultrasensitive detection of biomolecule. In this review, we summarize the latest Genosensor sensing applications of ECL bioanalysis in the field of bio affinity ECL sensors including aptasensors, im- Cytosensor Medical diagnostics munoassays and DNA analysis, cytosensor, molecularly imprinted sensors, ECL resonance energy transfer and Nanomaterials ratiometric biosensors and give future perspectives for new developments in ECL analytical technology. Furthermore, the results herein discussed would demonstrate that the use of nanomaterials with unique chemical and physical properties in the ECL biosensing systems is one of the most interesting research lines for the development of ultrasensitive electrochemiluminescence biosensors. In addition, ECL based sensing assays for clinical samples analysis and medical diagnostics and developing of immunosensors, aptasensors and cytosensor for this purpose is also highlighted.
    [Show full text]
  • Accomplishments in Nanotechnology
    U.S. Department of Commerce Carlos M. Gutierrez, Secretaiy Technology Administration Robert Cresanti, Under Secretaiy of Commerce for Technology National Institute ofStandards and Technolog}' William Jeffrey, Director Certain commercial entities, equipment, or materials may be identified in this document in order to describe an experimental procedure or concept adequately. Such identification does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment used are necessarily the best available for the purpose. National Institute of Standards and Technology Special Publication 1052 Natl. Inst. Stand. Technol. Spec. Publ. 1052, 186 pages (August 2006) CODEN: NSPUE2 NIST Special Publication 1052 Accomplishments in Nanoteciinology Compiled and Edited by: Michael T. Postek, Assistant to the Director for Nanotechnology, Manufacturing Engineering Laboratory Joseph Kopanski, Program Office and David Wollman, Electronics and Electrical Engineering Laboratory U. S. Department of Commerce Technology Administration National Institute of Standards and Technology Gaithersburg, MD 20899 August 2006 National Institute of Standards and Teclinology • Technology Administration • U.S. Department of Commerce Acknowledgments Thanks go to the NIST technical staff for providing the information outlined on this report. Each of the investigators is identified with their contribution. Contact information can be obtained by going to: http ://www. nist.gov Acknowledged as well,
    [Show full text]
  • Bioelectronics Contents
    chapter 10 Bioelectronics Contents Introduction . 253 Biosensors. 253 Biochips. 254 Priorities for Future Research . 256 Chapter IO References . 256 Figure Figure No. Page 29.The Use of Proteins in Constructing Circuit . ..., . 255 — Chapter 10 Bioelectronics .—— .— Introduction --—----- ——— The potential for the use of proteins in elec- used for several years, but design problems have tronic dmices has received attention recently with limited their acceptance. Biotechnology is ex- the advent of recombinant DNA (rDNA) technol- pected to increase the variety, stability, and sen- ogy}’ and the potential for computer-aided design sitivity of these devices. Biochips (biologically of proteins (I ,2,3 5 ,6,7, 11, 13,14,15,19,2 1 ). Work based microchips) capable of logic and memory is focused in two areas: biosensors and biochips. are still only speculative, and their development Biosensors (biological}’ based sensors) have been is many years away. Biosensors -——-- –—- —— .——. A potential application of biotechnology is in the not only could obviate the need for enzymes but development of improved sensing devices. Be- also could substantially broaden the applications cause of their high specificity. for given sub- of biosensors. A longer term solution to the lack of stances, enzymes and monocIonal antibodies particular enzymes might be to have computers (hlAbs) are particularly suited for use as sensors. design enzymes with particular catalytic func- Sensors using these biological molecules have the tions. Finally, features of proteins that determine potential to be smaller and more sensitive than temperature stability could be incorporated into traditional sensors. the genes that code for important sensing en- zymes. Biosensors using enzymes have been used to detect the presence of various organic compounds A new approach to fabrication is yielding bio- for many years (12).
    [Show full text]
  • An Aptamer-Based Magnetic Flow Cytometer Using Matched Filtering
    Biosensors and Bioelectronics 169 (2020) 112362 Contents lists available at ScienceDirect Biosensors and Bioelectronics journal homepage: http://www.elsevier.com/locate/bios An aptamer-based magnetic flow cytometer using matched filtering Chih-Cheng Huang a, Partha Ray b, Matthew Chan c, Xiahan Zhou c, Drew A. Hall c,d,* a Materials Science and Engineering Program, University of California – San Diego, La Jolla, CA, 92093, USA b Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, UC San Diego Health, La Jolla, CA, 92093, USA c Department of Electrical and Computer Engineering, University of California – San Diego, La Jolla, CA, 92093, USA d Department of Bioengineering, University of California – San Diego, La Jolla, CA, 92093, USA ARTICLE INFO ABSTRACT Keywords: Facing unprecedented population-ageing, the management of noncommunicable diseases (NCDs) urgently needs Aptasensor a point-of-care (PoC) testing infrastructure. Magnetic flow cytometers are one such solution for rapid cancer Flow cytometry cellular detection in a PoC setting. In this work, we report a giant magnetoresistive spin-valve (GMR SV) Magnetic biosensor biosensor array with a multi-stripe sensor geometry and matched filteringto improve detection accuracy without Matched filtering compromising throughput. The carefully designed sensor geometry generates a characteristic signature when Pancreatic cancer Point-of-Care (PoC) testing cells labeled with magnetic nanoparticles (MNPs) pass by thus enabling multi-parametric measurement like optical flow cytometers (FCMs). Enumeration and multi-parametric information were successfully measured across two decades of throughput (37 — 2730 cells/min). 10-μm polymer microspheres were used as a bio­ mimetic model where MNPs and MNP-decorated polymer conjugates were flown over the GMR SV sensor array and detected with a signal-to-noise ratio (SNR) as low as 2.5 dB due to the processing gain afforded by the matched filtering.
    [Show full text]
  • Biotechnology Past, Present and Potential
    4i-"l 11- HONORARY FELLOW'S ADDRESS TO IFST 20TH ANNIVERSARY SYMPOSIUM - 16 OCT. 1985 MANCHESTER, ENGLAND IDRC - 1-lb BIOTECHNOLOGY PAST, PRESENT AND POTENTIAL BY: JOSEPH H. HULSE* BIOTECHNOLOGY: ANCIENT AND MODERN Louis Pasteur wrote "There are no applied sciences; there are only applications of science...The study of the application of science is very easy to anyone who is master of the theory". A few years later Lord Kelvin instructed us that "If you can measure that of which you speak, and can express it by a number, you know something of your subject. But if you cannot measure it, your knowledge is meagre and unsatisfactory." It would indeed be interesting to know what the spirits of these distinguished scientists are thinkinq about "Biotechnology" which takes within its broad embrace remarkable new knowledge in cell and molecular biology; some very ancient technologies; together with a large swatch of enpirical observations and discoveries, many of which remain far distant from viable technological application. Fermentation technologies have a very long history: beer, wine, bread and cheese having been around as long as cereals and vine fruits have been harvested and animais have been milked. Homer described wine as a qift from the Gods and Ecclesiasticus wisely advised that "From the beginning wine was created to make men joyful, not to make them drunk." Though ethanolic fermentations have been most pervasive, lactic and other acidic fermentations have appeared in greater diversity, particularly in traditional domestic processes of preservation. The ancient Sumerians 7,000 years ago converted all their milk into cheese in the stated belief that had God intended mankind to have clean milk to drink he would have placed the udders at the front end of the cow.
    [Show full text]
  • Bioelectronics & Nanotechnology
    Bioelectronics & Nanotechnology A Master Degree in Biomedical Sciences – two years – full-time/part-time This unique master degree programme focuses on a novel and interdisciplinary scientific domain at the boundaries between physics, chemistry, electro- nics, and biomedical sciences. Fifty years ago, shortly after J. Watson and F. Crick successfully solved the structure of DNA using X-ray diffraction, R. Feynman made his visionary statement: “There’s plenty of room at the bottom”, with which he effectively heralded the new era of nanosciences. Since that time, research into “functi- onal” molecules and nanomaterials has developed into one of the most important scientific disciplines of today. This is triggered by the fact that a broad range of nanoscopic techniques has become available to study molecules directly at their own length scale and to understand their complex properties. The master programme offers a strong foundation in all fundamental scientific aspects and provides, in addition, an in depth introduction into several important application areas. Topics range from integrated detection and characterization techniques for molecules (biosensors) to the nanoscale engi- neering of implant materials, and the working principles of medical devices like neurochips and pacemakers. The curriculum of this programme was jointly developed by physicists, chemists, clinical and biomedical researchers, and engineers specialized in medi- cal instrumentation. The programme ensures therefore a broad overview of the domain of bioelectronics and nanotechnology and enables the graduates to develop their individual skills for a successful career in interdisciplinary research- and development environments. What are your career prospects ? Educational Concept • Applied and fundamental research at universities, hospitals, and research In view of the international profile of this degree programme, English langu- centers.
    [Show full text]
  • Science & Technology Trends 2020-2040
    Science & Technology Trends 2020-2040 Exploring the S&T Edge NATO Science & Technology Organization DISCLAIMER The research and analysis underlying this report and its conclusions were conducted by the NATO S&T Organization (STO) drawing upon the support of the Alliance’s defence S&T community, NATO Allied Command Transformation (ACT) and the NATO Communications and Information Agency (NCIA). This report does not represent the official opinion or position of NATO or individual governments, but provides considered advice to NATO and Nations’ leadership on significant S&T issues. D.F. Reding J. Eaton NATO Science & Technology Organization Office of the Chief Scientist NATO Headquarters B-1110 Brussels Belgium http:\www.sto.nato.int Distributed free of charge for informational purposes; hard copies may be obtained on request, subject to availability from the NATO Office of the Chief Scientist. The sale and reproduction of this report for commercial purposes is prohibited. Extracts may be used for bona fide educational and informational purposes subject to attribution to the NATO S&T Organization. Unless otherwise credited all non-original graphics are used under Creative Commons licensing (for original sources see https://commons.wikimedia.org and https://www.pxfuel.com/). All icon-based graphics are derived from Microsoft® Office and are used royalty-free. Copyright © NATO Science & Technology Organization, 2020 First published, March 2020 Foreword As the world Science & Tech- changes, so does nology Trends: our Alliance. 2020-2040 pro- NATO adapts. vides an assess- We continue to ment of the im- work together as pact of S&T ad- a community of vances over the like-minded na- next 20 years tions, seeking to on the Alliance.
    [Show full text]
  • Biosensing and Bioelectronics
    Rutgers University Electrical and Computer Engineering Department ECE 493/599 Biosensors and Bioelectronics Index Number 16320 Date: Fall 2015 Credits: 3 Time: TBA Location CORE 538 Grading 20% HW, 40% Midterm Exams, 10% Paper Presentation, 30% Final Project Final Exam None Instructor Mehdi Javanmard, PhD. Course TA: TBA Textbook: Kirby, Micro- and Nanoscale Fluid Mechanics (2010) Class slides will be available on the class website. Prerequisites: 14:332:361 Electronic Devices Further Reading: Saliterman, Fundamentals of BioMEMS and Medical Microdevices (2009) Stryer, Lubert Biochemistry 5th Edition (2008) Description of Course: The course covers state-of-the-art and emerging biosensors, biochips, microfluidics, which will be studied in the context of molecular diagnostics. Students will briefly learn the relevant biology, biochemistry, and molecular biology pertinent to molecular diagnostics and cancer. Students will also become equipped with a thorough understanding of the interfaces between electronics, optics, molecular biology, and cancer biology for engineers. Topics will include microfluidics and mass transfer limits, electrode-electrolyte interfaces, electrochemical noise processes, biosensor system level characterization, determination of performance parameters such as throughput, detection limit, and cost, integration of sensor with microfluidics, and electronic readout circuitry architectures Novel nanobiosensors such as nanopores, nanowire FETS, surface plasmon resonance, surface enhanced Raman scattering, fluorescence and single molecule detection will also be covered. Emphasis will be placed on hands-on in-depth quantitative design of biomolecular sensing platforms. Course intent 1. To introduce the major biochemical and molecular processes relevant in molecular diagnostics. 2. To introduce the major molecular processes relevant to cancer. 3.To introduce and provide an understanding of emerging micro- and nanotechnologies for biomarker based disease diagnosis.
    [Show full text]
  • Overview on the Detection, Interpretation and Reporting on the Presence of Unauthorised Genetically Modified Materials
    Overview on the detection, interpretation and reporting on the presence of unauthorised genetically modified materials Guidance document from the European Network of GMO Laboratories (ENGL) ENGL ad hoc working group on “unauthorised GMOs” EUR 25008 EN - 2011 The mission of the JRC-IHCP is to protect the interests and health of the consumer in the framework of EU legislation on chemicals, food, and consumer products by providing scientific and technical support including risk-benefit assessment and analysis of traceability. European Commission Joint Research Centre Institute for Health and Consumer Protection Contact information Address: Molecular Biology and Genomics Unit E-mail: [email protected] Tel.: +39 0332 789379 Fax: +39 0332 786159 http://ihcp.jrc.ec.europa.eu/ http://www.jrc.ec.europa.eu/ Legal Notice Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use which might be made of this publication. Europe Direct is a service to help you find answers to your questions about the European Union Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server http://europa.eu/ JRC 67297 EUR 25008 EN ISBN 978-92-79-21800-2 ISSN 1831-9424 doi: 10.2788/89665 Luxembourg: Publications Office of the European Union © European Union, 2011 Reproduction is authorised provided
    [Show full text]
  • Detection and Traceability of Genetically Modified Organisms In
    Food and Chemical Toxicology 42 (2004) 1157–1180 www.elsevier.com/locate/foodchemtox Detection and traceability of genetically modified organisms in the food production chain M. Miragliaa,*, K.G. Berdalb, C. Breraa, P. Corbisierc, A. Holst-Jensenb, E.J. Kokd, H.J.P. Marvind, H. Schimmelc, J. Rentsche, J.P.P.F. van Ried, J. Zagonf aIstituto Superiore di Sanita´, Section of Cereal Chemistry, Laboratory of Food, Viale Regina Elena 299, I-00161 Rome, Italy bNational Veterinary Institute, Section of Food and Feed Microbiology, Ullevaalsveien 68, N-0033 Oslo, Norway cEuropean Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Reference Materials Unit, Retieseweg, B-2440 Geel, Belgium dRIKILT-Institute of Food Safety, Wageningen University & Research Centre, Bornsesteeg 45, PO Box 230, NL-6700AE Wageningen, The Netherlands eMolecular Biology Unit, Swiss Quality Testing Services, Rte. de l’Industrie 61, CH-1784 Courtepin, Switzerland fCentre for Novel Foods and Genetic Engineering, Federal Institute for Risk Assessment, Thielallee 88-92, D-14195 Berlin, Germany Received 16 November 2003; accepted 4 February 2004 Abstract Both labelling and traceability of genetically modified organisms are current issues that are considered in trade and regulation. Currently, labelling of genetically modified foods containing detectable transgenic material is required by EU legislation. A pro- posed package of legislation would extend this labelling to foods without any traces of transgenics. These new legislations would also impose labelling and a traceability system based on documentation throughout the food and feed manufacture system. The regulatory issues of risk analysis and labelling are currently harmonised by Codex Alimentarius. The implementation and main- tenance of the regulations necessitates sampling protocols and analytical methodologies that allow for accurate determination of the content of genetically modified organisms within a food and feed sample.
    [Show full text]
  • NIST's Perspective on Bioelectronics
    November 4, 2008 David G. Seiler, Chief Semiconductor Electronics Division Electronics and Electrical Engineering Laboratory SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 1 NIST ◦ Innovation ◦ Bioscience and Health Bioelectronics: A New Frontier Summary SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 2 From E. Steel, “The Innovation Ecosystem,” June 2008. SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 3 From E. Steel, “The Innovation Ecosystem,” June 2008. SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 4 Biotechnology Bioscience and Health Is Identified as an Area for Significant Growth at NIST Adapted from W. May, “Overview of Partnerships with The Hollings Marine Laboratory and The University of Maryland Biotechnology Institute,” June 10, 2008. SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 5 It is congruent with our mission, and indeed our mandate, to support U.S. industry and other stakeholders in overcoming measurement and standards-related challenges in the biosciences by leveraging our vast multidisciplinary expertise in the quantitative physical and informational sciences, to: . provide the measurement infrastructure to provide confidence in the results from measurements of complex biological systems Which will . enable and facilitate realization of optimal economic and broad societal benefits from new innovations SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 6 • FY07 Budget Increase Calibration and IT standards for MRI, CT, PET and cellular imaging • FY09 Budget Request Technology and standards for
    [Show full text]
  • Biosensors and Bioelectronics Bioelectrochemical Systems
    Biosensors and Bioelectronics 142 (2019) 111576 Contents lists available at ScienceDirect Biosensors and Bioelectronics journal homepage: www.elsevier.com/locate/bios Bioelectrochemical systems: Sustainable bio-energy powerhouses T ∗ Mahwash Mahar Gul, Khuram Shahzad Ahmad Department of Environmental Sciences, Fatima Jinnah Women University, The Mall, Rawalpindi, 46000, Pakistan ARTICLE INFO ABSTRACT Keywords: Bioelectrochemical systems comprise of several types of cells, from basic microbial fuel cells (MFC) to photo- Microbial fuel cells synthetic MFCs and from plant MFCs to biophotovoltaics. All these cells employ bio entities at anode to produce Photo MFCs bioenergy by catalysing organic substrates while some systems convert solar irradiation to energy. The current Plant MFCs review epitomizes the above-mentioned fuel cell systems and elucidates their electrical performances. Microbial Biophotovoltaics fuel cells have advantages over conventional fuel cells in terms of being sustainable whilst producing impressive Bioelectricity power efficiencies without any net carbon emissions. They can be utilized for several environmentally friendly applications including wastewater treatment and bio-hydrogen generation, apart from producing clean and green electricity. Multifarious heterotrophic and autotrophic microbes and plants have been studied for their potential as imperative components of fuel cell technology. MFCs also display some interesting applications, such as integration of plant MFCs into architecture to produce “green” cities. Biophotovoltaic technology is the current hot cake in this field, which aspires to achieve significant electrical efficiencies by light-induced water splitting mechanisms. Furthermore, the utilization of BPVs in space renders it a technology for the future. Compared with other fuel cell systems, this technology is still in its inception and requires further efforts to endeavour its use on commercial or industrial level.
    [Show full text]